Basilea Pharmaceutica AG (BSLN) — Capital Reinvestment Ratio

Latest as of December 2025: 0.06x

Basilea Pharmaceutica AG (BSLN) has a Capital Reinvestment Ratio of 0.06x as of December 2025, meaning it reinvests 0% of its operating cash flow (CHF39.03 Million) in capital expenditures (CHF2.30 Million). See net asset quality index of Basilea Pharmaceutica AG to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.06x
Capex / Operating Cash Flow

Operating Cash Flow

CHF39.03 Million
CHF

Capital Expenditures

CHF2.30 Million
CHF

Data as of

Dec 2025
Most recent filing

Basilea Pharmaceutica AG Capital Reinvestment Ratio (2005–2025)

This chart tracks Basilea Pharmaceutica AG's Capital Reinvestment Ratio across 8 annual periods. Check Basilea Pharmaceutica AG cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Basilea Pharmaceutica AG (2005–2025)

Year-by-year Capital Reinvestment Ratio for Basilea Pharmaceutica AG from 2005 to 2025. For live market cap and broader valuation context, see how much is Basilea Pharmaceutica AG worth.

Year Reinvestment Ratio Operating CF (CHF) Capital Expenditures YoY Change
2025 0.04x CHF62.09 Million CHF2.62 Million ▲ +83.5%
2024 0.02x CHF74.36 Million CHF1.71 Million ▼ -68.3%
2023 0.07x CHF14.24 Million CHF1.03 Million ▼ -84.5%
2022 0.47x CHF7.06 Million CHF3.30 Million ▲ +1151.9%
2017 0.04x CHF19.01 Million CHF711.00K ▲ +319.3%
2012 0.01x CHF148.17 Million CHF1.32 Million ▼ -23.3%
2010 0.01x CHF106.64 Million CHF1.24 Million ▼ -66.7%
2005 0.03x CHF34.38 Million CHF1.20 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow